DiscoverImmuno-Oncology
Immuno-Oncology has emerged as an exciting strategy for the treatment of cancers with long term responses.
XenTech has developed syngeneic and PDX based models that can be used for the in-depth profiling of the immune response against tumors.
XenTech offers syngeneic models for check-point inhibitors and combination studies.
XenTech offers also Immuno-Oncology models with delayed GVHD using PDX
Adoptive approaches (T-cell or NK-cell-based)
hBPMC humanized models.
01Flow Cytometry
XenTech offers in depth immunophenotyping for comprehensive cell characterization.
Analyses are performed on blood and tumours.
For syngeneic models.
Our FACS analysis allow phenotyping of circulating as well as infiltrating cells through 2 different panels
T/T reg
- CD8+ T cells (CD45+, CD3+, CD4-, CD8+)
- CD4+ T cells (CD45+, CD3+, CD4+, CD8-)
- Treg (CD4+, CD127low, CD25+)
MDSC/LB/NK
- Mo-MDSC (CD45+, CD11b+, Ly6C+, Ly6G-)
- G-MDSC (CD45+, CD11b+, Ly6C-, Ly6G+)
- Macrophage (CD45+, CD11b+)
- LB (CD19+)
- NK cells (CD45+, CD56+, CD16+)
For PBMC Humanized models.
Our FACS analysis allow phenotyping of circulating and infiltrating h-T/T/ reg cells through our standard panel
- CD8+ T cells (CD45+, CD3+, CD4-, CD8+)
- CD4+ T cells (CD45+, CD3+, CD4+, CD8-)
- Treg (CD4+, CD127low, CD25+)
